Search hospitals > North Carolina > Wilmington
Novo Nordisk Investigational Site
Claim this profileWilmington, North Carolina 28401
Global Leader in Diabetes
Global Leader in Type 2 Diabetes
Conducts research for Hemophilia A
Conducts research for Hemostatic Disorders
Conducts research for Blood Clotting Disorders
270 reported clinical trials
0 medical researchers
Summary
Novo Nordisk Investigational Site is a medical facility located in Wilmington, North Carolina. This center is recognized for care of Diabetes, Type 2 Diabetes, Hemophilia A, Hemostatic Disorders, Blood Clotting Disorders and other specialties. Novo Nordisk Investigational Site is involved with conducting 270 clinical trials across 80 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Diabetes
Global LeaderStage II
Stage I
2Type 2 Diabetes
Global LeaderStage II
Stage I
Top PIs
Clinical Trials running at Novo Nordisk Investigational Site
Type 2 Diabetes
Hemophilia A
Turner Syndrome
Diabetes
Obesity
Chronic Kidney Disease
Cardiovascular Disease
Noonan Syndrome
Syndrome
Hemophilia
Semaglutide + Low-Dose Insulin Glargine
for Type 2 Diabetes
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
Recruiting2 awards Phase 34 criteria
CagriSema
for Type 2 Diabetes
This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.
Recruiting1 award Phase 36 criteria
Oral Semaglutide
for Type 2 Diabetes in Youth
This trial is testing a new diabetes medicine called semaglutide. It focuses on children and teenagers with type 2 diabetes to see if the new medicine is safe and effective. Semaglutide helps control blood sugar levels, which is crucial for managing diabetes. It has been shown to improve blood sugar control and promote weight loss in patients with type 2 diabetes.
Recruiting1 award Phase 37 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novo Nordisk Investigational Site?
Novo Nordisk Investigational Site is a medical facility located in Wilmington, North Carolina. This center is recognized for care of Diabetes, Type 2 Diabetes, Hemophilia A, Hemostatic Disorders, Blood Clotting Disorders and other specialties. Novo Nordisk Investigational Site is involved with conducting 270 clinical trials across 80 conditions. There are 0 research doctors associated with this hospital, such as .